End-to-end analytical and imaging support for oncology programs — radiolabeling quality control, quantitative image analysis, nanomedicine characterization, custom nanomaterial synthesis, defect-engineered heterojunction analysis, and electrochemical biosensor design and validation, built to answer one question: will your construct, material, or device perform as designed?
Analytical and imaging programs rarely fail for lack of an instrument. They fail because the right measurement was never designed — a radiolabel that passes radio-TLC but hides radiolysis, a nanoparticle whose average size is reported but whose batch-to-batch consistency is not, or a biosensor validated on a single spike yet never challenged with a real sample matrix.
Alfa Oncology's advanced analytical and imaging service line addresses each of these gaps with Radiolabeling and Quality Control Services, Quantitative Image Analysis for Preclinical Imaging Biomarkers Services, Comprehensive Physicochemical Characterization for Nanoparticle-Based Therapeutics Services, Precision-Engineered Nanomaterials for Your Research Services, Defect-Engineered Heterojunction Analysis Services, Custom Electrochemical Biosensor Prototyping from Concept to Functional Device Services, and Independent Performance Validation for Your Biosensor Device Services — so that specification, characterization, and independent verification are generated under one program rather than stitched together across vendors.
Every project runs through documented protocols, QC checkpoints, and interpretive reporting, supporting go/no-go decisions from lead optimization through IND-enabling studies.
Each module stands alone or combines into a complete analytical and imaging package — from radiolabeling QC and quantitative image analysis through nanomaterial synthesis, heterojunction analytics, and biosensor design and independent validation.
GMP-grade radiolabeling with radio-TLC/HPLC cross-validation and radiochemical purity testing for therapeutic radiopharmaceuticals including [177Lu]Lu-PSMA, with radiolysis detected by HPLC rather than radio-TLC alone.
Learn More →Reproducible quantification of PET, SPECT, CT, and optical imaging readouts — tumor burden, tracer uptake, and longitudinal imaging biomarkers delivered through documented, auditable analysis pipelines.
Learn More →Size, zeta potential, encapsulation efficiency, lipid species, and stability profiling for liposomes and lipid nanoparticles, mapped to the critical quality attributes that drive in vivo performance.
Learn More →Custom synthesis of polymeric and inorganic nanoparticles to specification, with batch characterization and scale-up support for drug-delivery, imaging, and theranostic applications.
Learn More →Photoelectrochemical and heterostructure material analytics — band alignment, defect states, and photoactive performance characterization — for sensing, catalysis, and energy-material programs.
Learn More →Electrode functionalization, assay design, and prototype fabrication — from concept to a working screen-printed or chip-based biosensor with defined sensitivity and selectivity.
Learn More →Vendor-neutral validation against ICH/CLSI analytical performance criteria — selectivity, LOD/LOQ, precision, accuracy, and matrix effects — so device claims withstand review.
Learn More →Define your modality, material, or device, the decision endpoint, and the regulatory bar; we scope assays, standards, and acceptance criteria around your question.
Qualify radiochemical batches, nanoparticle lots, heterojunction films, or biosensor prototypes, with method parameters and reference materials documented before measurement.
Radio-HPLC, imaging quantification, light scattering and spectroscopy, PEC characterization, and electrochemical measurement run on your samples under QC.
Batch certificates, measurement tables, calibration curves, and interpretation-ready reports with a scientific debrief to support your next development decision.
Analytical and imaging readouts link directly to our preclinical and disease model resources across hematologic and solid indications.
Teams experienced in radiochemistry, imaging quantification, nanomaterial analytics, and biosensor engineering rather than generic assay services.
Radiolabeling, imaging, nanomaterial, heterojunction, and biosensor workflows delivered within one program instead of across vendors.
Assay panels, material specs, and validation criteria are scoped to your target, indication, and decision point instead of fixed menus.
Validated protocols, QC checkpoints at every processing step, and traceable reporting so results withstand internal review and regulatory scrutiny.
Selected peer-reviewed publications underpinning the methodologies behind our analytical and imaging platforms.
Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA (Hooijman et al., 2022)
View article →Analytical characterization of liposomes and other lipid nanoparticles for drug delivery (Fan et al., 2021)
View article →Recent progress of heterostructure-based photoelectrodes in photoelectrochemical biosensing: a mini review (Wang et al., 2020)
View article →Yes. Our Radiolabeling and Quality Control Services cross-validate radio-TLC against HPLC so radiolysed constructs — which radio-TLC frequently fails to flag — are identified, and radiochemical purity is reported before release.
Our Quantitative Image Analysis for Preclinical Imaging Biomarkers Services apply documented segmentation, registration, and longitudinal pipelines across PET, SPECT, CT, and optical modalities, reporting tumor burden and tracer uptake as auditable metrics rather than single-snapshot reads.
Comprehensive Physicochemical Characterization for Nanoparticle-Based Therapeutics Services cover size, zeta potential, encapsulation efficiency, lipid species, and stability, mapped to the critical quality attributes that govern batch consistency and in vivo behavior.
Yes. Precision-Engineered Nanomaterials for Your Research Services deliver polymeric or inorganic nanoparticles built to your size, surface, and loading targets, with batch characterization and scale-up support for downstream studies.
Yes. Defect-Engineered Heterojunction Analysis Services characterize band alignment, defect states, and photoactive performance of heterostructure films for sensing, catalysis, and energy-material programs.
Yes. Independent Performance Validation for Your Biosensor Device Services run vendor-neutral testing against ICH/CLSI analytical performance criteria, and can be paired with Custom Electrochemical Biosensor Prototyping from Concept to Functional Device Services when a device needs both build and independent proof.
Tell us about your radiopharmaceutical, nanomaterial, or biosensor — our scientists will propose a study design covering the right combination of QC, imaging, and analytical readouts within 1–2 business days.